The emails keep coming through, usually a week or two after an order was placed: batch on hold, shipment delayed, please bear with us. I’ve been on the receiving end of three of these now, and for a while I read them the way they were framed, as a logistics or fulfilment problem. Having spent some time since then reading what USP pharmacopeial chapter <71> actually requires for sterile product lot release, I think that framing is missing the real constraint. USP <71> sterility testing requires 14 days of incubation. That window exists because the organisms that matter, particularly slow-growing anaerobes, will not produce a detectable result any faster. A 503B compounder cannot release a batch for distribution until that incubation closes and the result comes back negative. So when an order is delayed by two weeks, that is frequently not a pharmacy moving slowly. That is the testing requirement doing exactly what it is supposed to do. The part I keep coming back to: a passing sterility result is a probabilistic inference about the lot, not a certificate for any individual vial. USP <71> samples, it does not test every unit. “Lot passed sterility” and “your vial is sterile” are not the same claim, and that distinction sits underneath the compounded versus brand quality conversation in a way that rarely gets named. Some pharmacies use rapid alternative sterility methods under chapter <1071> that do not need the full 14-day window, but those methods require validation and are not universal. Which means for most people evaluating a source, the endotoxin testing question tends to be more immediately actionable than asking about the sterility timeline. Endotoxin results come back faster, and endotoxin contamination is the more acutely symptomatic risk. None of this makes the waiting easier. But it reframes the delay as a quality constraint rather than disorganisation.